Multiple Myeloma

Enrollment Completed For Phase II Trial Of LDP-341

Published in Cancer Weekly, November 6th, 2001

Millennium Pharmaceuticals, Inc. announced that it has completed enrollment of a Phase II clinical trial of LDP-341 (formerly PS-341) in patients with multiple myeloma. The accrual was completed ahead of schedule and the trial has been extended to capture additional clinical data.

LDP-341, the first investigational drug candidate in a new class of anticancer agents, is a small molecule proteasome inhibitor in clinical development by Millennium as a novel potential therapy for several forms of hematologic and solid tumor cancers.

The multicenter trial, initiated in February 2001, is an open-label study of LDP-341 alone or in combination with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry